# OrphanCure Full Pipeline Report: repodb_3662c26db0147ddc

- Drug: Paclitaxel
- Disease: Pancreatic adenocarcinoma metastatic
- Mode: no_verifier
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Paclitaxel shows potential for repurposing in colorectal adenocarcinoma, with multiple studies investigating its use in novel drug delivery systems and combination therapies. While direct clinical evidence for paclitaxel as a standalone treatment for colorectal adenocarcinoma is limited in the provided literature, its established role in other cancers and its investigation in CRC models suggest a potential therapeutic benefit.",
      "evidence_counts": {
        "total_papers": 36,
        "supporting": 10,
        "contradicting": 2,
        "inconclusive": 24
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose PACLITAXEL for colorectal adenocarcinoma",
      "drug": {
        "id": "CHEMBL428647",
        "name": "PACLITAXEL",
        "aliases": [
          "Taxol",
          "Paclitaxel",
          "Abraxane",
          "PTX",
          "Taxol (paclitaxel)"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_0000365",
        "name": "colorectal adenocarcinoma",
        "aliases": [
          "Adenocarcinoma of colon and rectum",
          "Colorectal cancer",
          "Colon and rectum adenocarcinoma",
          "Adenocarcinoma, colon and rectum",
          "Colorectal adenocarcinomas"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 36,
      "polarity": {
        "supports": 10,
        "contradicts": 2,
        "inconclusive": 24
      },
      "support_ratio": "10 of 36 retrieved papers support the hypothesis",
      "queries_used": 9,
      "top_papers": [
        {
          "pmid": "39372162",
          "title": "Revealing the Unanticipated: An Uncommon Case of Colorectal Adenocarcinoma Transitioning to Choriocarcinoma - A Case Report and Literature Review.",
          "year": "2024",
          "relevance_score": 8.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Recent"
          ]
        },
        {
          "pmid": "38494800",
          "title": "[History and Perspective of Chemotherapy in Advanced Esophageal Cancer].",
          "year": "2024",
          "relevance_score": 8.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "37244399",
          "title": "Piperine analog PGP-41 treatment overcomes paclitaxel resistance in NCI/ADR-RES ovarian cells by inhibition of MDR1.",
          "year": "2023",
          "relevance_score": 7.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "40189171",
          "title": "Polymer-lipid hybrid microcarriers for oral codelivery of paclitaxel and tributyrin: development, optimization, and cytotoxicity in cells and spheroids of colorectal cancer.",
          "year": "2025",
          "relevance_score": 7.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "39917727",
          "title": "Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach.",
          "year": "2025",
          "relevance_score": 7.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "38143740",
          "title": "Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.",
          "year": "2023",
          "relevance_score": 6.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "41408639",
          "title": "Role of LINC00332 in colorectal cancer progression and paclitaxel resistance.",
          "year": "2025",
          "relevance_score": 6.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "32548664",
          "title": "PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.",
          "year": "2020",
          "relevance_score": 6.0,
          "polarity": "SUPPORTS",
          "match_reasons": []
        },
        {
          "pmid": "38463225",
          "title": "Case report: Pathological complete response of pregnancy associated pulmonary enteric adenocarcinoma to chemoradiotherapy.",
          "year": "2024",
          "relevance_score": 6.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Recent"
          ]
        },
        {
          "pmid": "40323277",
          "title": "DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.",
          "year": "2025",
          "relevance_score": 6.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Clinical study",
            "Recent"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "Medium",
        "literature_strength": "Medium",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.787,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "3/3 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "6 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/3 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "3/3 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "2 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Drug resistance is a common challenge in cancer treatment, including for paclitaxel.",
        "Paclitaxel is a known chemotherapy agent with significant side effects."
      ],
      "limitations": [
        "The provided literature primarily focuses on preclinical investigations and novel delivery systems for paclitaxel in colorectal cancer models, rather than direct clinical application.",
        "Some papers discuss paclitaxel in the context of other cancers or as a comparator, requiring careful interpretation for colorectal adenocarcinoma.",
        "The abstract snippets do not provide comprehensive details on experimental design or statistical significance."
      ],
      "missing_data": [
        "Direct clinical trial data for paclitaxel in colorectal adenocarcinoma.",
        "Information on optimal dosing and administration for paclitaxel in colorectal adenocarcinoma.",
        "Studies directly comparing paclitaxel to current standard-of-care for colorectal adenocarcinoma."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct clinical trials to evaluate the efficacy and safety of paclitaxel, potentially in combination therapies or novel delivery systems, for colorectal adenocarcinoma.",
        "Investigate biomarkers that predict response or resistance to paclitaxel in colorectal adenocarcinoma."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 3,
      "claims": [
        {
          "claim_id": "CLM-b24e57",
          "statement": "Paclitaxel is investigated as a therapeutic agent for colorectal cancer, often in combination or advanced delivery systems.",
          "confidence_numeric": 0.7,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-17f0df",
          "statement": "Paclitaxel resistance in colorectal cancer can be influenced by factors like LINC00332.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-40b67b",
          "statement": "Paclitaxel resistance in cancer cells can be modulated by compounds that inhibit P-glycoprotein (P-gp).",
          "confidence_numeric": 0.7,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 3,
      "entries": [
        {
          "claim_id": "CLM-b24e57",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "dc3e7b33d7ef",
          "timestamp": "2026-06-03T14:37:43.006421+00:00",
          "paper_evidence": [
            {
              "pmid": "40189171",
              "snippet": "In this study, a polymer-lipid hybrid microcarrier was developed for oral co-administration of paclitaxel (PTX) and tributyrin (TB) as a novel approach for CRC therapy.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "39917727",
              "snippet": "Alantolactone (A) was found to augment the anticancer efficacy of paclitaxel (P) at a molar ratio of 1:0.5 (P:A) through induction of more potent ICD via modulation of STAT3 signaling pathways.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "32548664",
              "snippet": "Development of a nanoplatform constructed by the PEG-dual drug conjugation for co-delivery of paclitaxel (PTX) and Dihydroartemisinin (DHA) to the tumor.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "38494800",
              "snippet": "CF(cisplatin plus 5-FU)therapy and taxanes( paclitaxel or docetaxel)were considered standard treatments for first- and second-line treatment of advanced esophageal carcinoma based on the results of ph",
              "polarity": "INCONCLUSIVE",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 9
        },
        {
          "claim_id": "CLM-17f0df",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "dc3e7b33d7ef",
          "timestamp": "2026-06-03T14:37:43.006421+00:00",
          "paper_evidence": [
            {
              "pmid": "41408639",
              "snippet": "Role of LINC00332 in colorectal cancer progression and paclitaxel resistance.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 9
        },
        {
          "claim_id": "CLM-40b67b",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "dc3e7b33d7ef",
          "timestamp": "2026-06-03T14:37:43.006421+00:00",
          "paper_evidence": [
            {
              "pmid": "37244399",
              "snippet": "Paclitaxel is one of the first lines of drugs for treating ovarian cancer and is a substrate of P-gp; therefore, NCI/ADR-RES cells are highly resistant to treatment with paclitaxel.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 9
        }
      ]
    }
  },
  "metadata": {
    "run_id": "dc3e7b33d7ef",
    "created_at": "2026-06-03T14:37:22.657915+00:00",
    "drug": "PACLITAXEL",
    "disease": "colorectal adenocarcinoma",
    "total_claims": 3,
    "quality_score": 0.7875,
    "reruns": 0
  }
}
```
